Medical Patent News

RSS

Indonesia issues order to override patents on 7 HIV, hepatitis drugs

"Indonesia's government has quietly issued an order to override the patents on seven important medicines used to treat people with HIV and hepatitis B and allow cheap versions to be made by local drug companies," Guardian Health Editor Sarah Boseley reports in her "Global Health Blog."

15 Oct 2012

Cellectricon settles patent infringement litigation with Fluxion

Cellectricon AB and Fluxion Biosciences today announced that they have settled the patent infringement litigation that Cellectricon commenced against Fluxion in 2009.

From Fluxion Biosciences 15 Oct 2012

MSF launches online 'Patent Opposition Database'

"The international medical humanitarian organization Doctors Without Borders/Medecins Sans Frontieres (MSF) has launched an online resource to help civil society and patient groups in developing countries challenge unwarranted drug patents," an MSF press release reports.

10 Oct 2012

Mylan, Shionogi and CIMA Labs to resolve generic Orapred ODT patent litigation

Mylan Inc. today announced that it has entered into a settlement agreement with Shionogi Inc. and CIMA Labs Inc. that will resolve patent litigation related to Prednisolone Sodium Phosphate Orally Disintegrating Tablets (ODT), 10 mg, 15 mg and 30 mg.

10 Oct 2012

USPTO grants five-year extension to Spectrum's FOLOTYN patent

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the United States Patent and Trademark Office (USPTO) has extended by five years the U.S. Patent No. 6,028,071, which covers FOLOTYN (pralatrexate injection).

8 Oct 2012

SpineSmith receives U.S. patent for VisuALIF lumbar interbody device

SpineSmith, a Celling Biosciences company, announces that the United States Patent and Trademark Office has issued US Patent 8,273,127, covering the VisuALIF, the first lumbar interbody device featuring a revolutionary open-face design.

4 Oct 2012

Two court cases could affect medicines patent law in India

In the PLoS "Speaking of Medicine" blog, Leena Menghaney, a lawyer and India manager of the Access Campaign at Medecins Sans Frontieres, writes about "two critical legal battles between multinational pharmaceutical companies and the Indian government that are taking center stage in an ongoing struggle over India's medicines patent law."

3 Oct 2012

Financial Times examines legal disputes in India over pharmaceutical patent laws

The Financial Times reports on a legal dispute between the Indian government and the German pharmaceutical group Bayer, writing, "Bayer is appealing against the Indian patent controller's decision in March to override the company's monopoly on its cancer drug Nexavar, and to allow an Indian company to produce and sell the life-extending drug for just $173 a month -- one-sixth of the $5,500 a month price charged by Bayer."

3 Oct 2012

EPO grants patent to Rexahn’s new isoquinolinamine compounds for cancer

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 2099765 to Rexahn, entitled "5, 6, or 7-Substituted-3-arylisoquinolinamine derivatives as antitumor agents."

27 Sep 2012

Alitair receives U.S. patent allowance for ion exchange resin formulation of benzonatate

Alitair Pharmaceuticals, Inc., today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its ion exchange resin formulation of benzonatate.

27 Sep 2012

U.S. District Court rules in favor of Alnylam in patent infringement case against Tekmira

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the U.S. District Court of the District of Massachusetts has ruled in favor of Alnylam and has denied Tekmira Pharmaceuticals Corporation's motion to dismiss certain claims and motion to disqualify Alnylam's counsel in an infringement suit filed in January 2012.

26 Sep 2012

EPO grants patent to Aeterna Zentaris’ AEZS-130 for diagnosis of growth hormone deficiency

Aeterna Zentaris Inc. today announced that the European Patent Office has granted a patent for the use of the ghrelin agonist, AEZS-130, related to methods and kits for use in relation to the diagnosis of growth hormone deficiency in a human or animal subject.

25 Sep 2012

BioLineRx receives U.S. patent allowance for BL-1020 to treat schizophrenia

BioLineRx, a biopharmaceutical development company, announced today that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) claiming the crystalline form of BL-1020, a first-in-class orally available treatment for schizophrenia.

24 Sep 2012

Titan Spine receives U.S. patent for competitive interbody devices

Titan Spine, a medical device surface technology company focused on the development of innovative spinal interbody fusion implants, announced today that it has been awarded patent #US 8,262,737 B2 by the United States Patent Office that protects the Company against competitive interbody devices with a roughened surface topography, anti-expulsion edges, and access to a hollow center.

21 Sep 2012

Pending cases against India's patent laws threaten public health, misinterpret international IP agreements, report says

"Pending cases against India's patent laws threaten public health and misinterpret international intellectual property (IP) agreements," researchers from Queen Mary, University of London argue in a special report published online in the Lancet on Monday, PharmaTimes reports.

13 Sep 2012

Acacia subsidiary obtains patent for stent graft technology

Acacia Research Corp announced today that a subsidiary has acquired a patent for stent graft technology.

11 Sep 2012

Bio DG’s novel metal system receives U.S. patent for use in implantable medical devices

Bio DG announced today that its patent for a novel metal system for use as biodegradable material in developing implantable medical devices was granted by the U.S. Patent Office on August 21, 2012.

11 Sep 2012

Jazz Pharmaceuticals receives new U.S. patent for Xyrem oral solution

Jazz Pharmaceuticals plc. today announced that a new patent related to Xyrem (sodium oxybate) oral solution titled "Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for the Treatment of Narcolepsy" will issue today.

11 Sep 2012

Pfizer announces settlement of Detrol LA patent litigation with Mylan

Pfizer Inc. announced that it has settled its litigation against Mylan Inc. and Mylan Pharmaceuticals Inc. relating to Pfizer's patents covering Detrol LA (tolterodine tartrate) extended-release capsules.

7 Sep 2012

Pfizer, Mylan enter settlement agreement to resolve generic Detrol LA litigation

Mylan Inc. today announced that it and its subsidiary, Mylan Pharmaceuticals Inc., have entered into a settlement agreement with Pfizer Inc., Pharmacia & Upjohn Company LLC and Pfizer Health AB that will resolve the parties' patent litigation in connection with Mylan Pharmaceuticals' Abbreviated New Drug Application (ANDA) for Tolterodine Tartrate ER capsules, 2 mg and 4 mg, which is the generic version of Pfizer's Detrol LA, indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

7 Sep 2012